The nonapeptide YAGAWNDL has previously been shown to specifically inhibit ribonucleotide reductase (RR) induced by herpes simplex virus (HSV) and other herpesviruses. The stability of this peptide has been examined in extracts of HSV-infected cells. It was found to be rapidly modified to yield free tyrosine and the octapeptide AGAWNDL. Modification could be inhibited by several protease inhibitors, suggesting that it arises through cleavage of the amino-terminal tyrosine peptide bond. The implications of these results for the development of a therapeutically useful drug based on the nonapeptide are discussed.
Ribonucleotide reductase (RR) reduces all four ribonucleotides to the corresponding deoxyribonucleotides and so catalyses the first specific step in DNA synthesis (reviewed by Thelander and Reichard, 1979; Lammers and Follmann, 1983; Eriksson and Sjoberg, 1989; Reichard, 1988) . Several herpesviruses induce a novel RR in virusinfected cells, and for herpes simplex virus (HSV) this activity is virus-coded (Dutia), 1983; Preston et al., 1988) . The virus enzyme is biochemically and immunologically distinct from its cellular counterpart (Averett et al., 1983; Bacchetti et al., 1986; Preston et al., 1984) , making it a potential target for antiviral chemotherapy. Support for this view is provided by the studies of Cameron et al. (1988) and Jacobson et al. (1989) , who showed that the HSV RR enzyme is a determinant of the pathogenicity of the virus in mice.
The HSV-coded enzyme comprises two non-identical subunits (Frame et al., 1985; Bacchetti et al., 1986; Ingemarsson and Lankinen, 1987; Darling et al., 1988; Huang et al., 1988) , termed RR1 and RR2 (Frame et al., 1985) . Sedimentation analysis of the enzyme suggests that both subunits are present as homodimers with the same basic <X2!32 structure as the Escherichia coli and mammalian reductases (Ingemarsson and Lankinen, 1987) .
The HSV-induced RR activity was found to be specifically inhibited by the nonapeptide YAGAWNDL, which corresponds to the carboxy-terminal nine amino acids of RR2 (Dutia et al., 1986; Cohen et al., 1986) . Further studies showed that the RR enzymes induced by pseudorabies virus and equine herpesvirus type 1 (Telford et al., 1990) are also inhibited by the nonapeptide, suggesting that if an antiviral drug based on the nonapeptide could be developed then it might be effective against a broad range of herpesviruses.
The peptide acts by blocking the interaction between the RR1 and RR2 subunits (McClements et al., 1988) . Direct evidence demonstrating that the inhibitory nonapeptide competes with RR2 for a binding site on RR1 has been reported by Paradis et al. (1988) .They showed that a photoreactive analogue of the nonapeptide bound specifically to the HSV-1-induced RR1 polypeptide. This covalent association of the photoaffinity-Iabelled peptide with RR1 produced an irreversible inhibition of ribonucleotide reductase activity. The peptide is thought to be able to gain access to the binding site for RR2 on RR1 because the two subunits exist in equilibrium between associated and dissociated states (Darling et al., 1990) . Binding of peptide to RR1 would thus inhibit the functionally essential reassociation of the subunits.
One of the long-term objectives of our research is to explore fully the possibility of developing a therapeutically useful drug based on essential aspects of the inhibitory nonapeptide. The aim of the experiments reported here was to determine nonapeptide stability in cellular extracts and to identify the nature of any modifications observed.
Peptides were synthesized by continuous flow Fmoc chemistry (reviewed by Atherton et al., 1979; Sheppard, 1983) , as described previously (Lankinen et al., 1989) . They were purified by preparative reverse-phase high pressure liquid chromatography (HPLC)and were found to be better than the 99% pure by analytical reverse-phase HPLC monitored at 229nm. The M r of the peptides were Table 1 . Identification of the main peaks observed following incubation ofYAGAWNDL with an extract of HSV-1-infected cells.
min. However, when the diluent was HSV-1-infected cell extract, two peaks of radioactivity were observed ( Fig. 1b ). One ofthese peaks eluted atthe same time as [3HjYAGAV-VNDL and the other eluted at 5 min 12 seconds. As shown in Fig. 1b , there was thus approximately 70% conversion to a new species within 2 min, the time taken for injection.
To investigate whether an infected cell protease caused this modification of the nonapeptide, 4!J..Ci rH)YAGAV-VNDL were mixed with 100!J..1 HSV-1-infected cell extract containing the following protease inhibitors at concentrations typical of those normally used to protect proteins: PMSF (1 mM), TPCK (0.5mM), bacitracin (1 mM), leupeptin (10-7 M) (all obtained from Sigma, London, UK) or alpha 2 macroglobulin (0.3 inhibitory units mr': BCL, Boehringer Mannheim, Lewes, UK). Each sample was prepared immediately prior to analysis by HPLC. As opposed to 70% conversion without inhibitors, PMSF allowed 40% conversion, TPCK 40% conversion, and bacitracin 20% conversion. Little or no protection was afforded by pepstatin A, leupeptin and alpha 2 macroglobulin (data not shown). This observation that protease inhibitors could stabilize the peptide suggests that the modification is due to proteolytic cleavage.
To identify them, the modified products of YAGAWNDL were purified by preparative reverse-phase HPLC. To generate SUfficient quantities of the products for further analysis, 3 ml of a 4 mg mr' (w/v) solution of YAGAWNDL were mixed with 260!J..1 HSV-1-infected cell extract and the mixture was incubated at room temperature for 3 h. The products of the reaction were purified using a Waters uBondapak C18 preparitive column and the eluant was monitored at 229 nm. Figure 2 shows that under these conditions, three main species were eluted from the preparative column. The first, Peak 1, was eluted at 12 min 32 seconds, the second, peak 2, was eluted at 19 min 13 seconds and the third, Peak 3, was eluted at 20 min 21 seconds. The peaks were collected and analysed using the analytical column, which established that the three peaks had been effectively purified (data not shown).
A small amount of each of the three peaks was analysed for amino acid composition and relative molecular mass by fast atom bombardment mass spectroscopy. The results are shown in Table 1 and indicate that Peak 1 was free tyrosine, Peak 2 was the octapeptide AGAWNDL and Peak 3 was the nonapeptide YAGAWNDL. 224 E. Telford, A. Owsianka and H. Marsden Fig. 1 . Modification of the nonapeptide YAGAWNDL by extracts of HSV-1-infected cells. 4JLCi["HIYAGAWNDL were mixed with either 100 fLl H20 (a) or with 100 fLlpartially purified HSV-1-infected cell extract (b). Each sample (25fLl) was analysed by reverse-phase HPLC (using a Waters uBondapak C18 column 8mm x 10cm) in a linear gradient increasing from 5% to 95% acetonitrile in H 2 0 + 0.1% TFA between 0 and 10 min and the tritium was measured using a flow through scintillation counter. determined by mass spectrometry (M-Scan Ltd, Cambridge, UK), which gave values identical to those expected.
A tritiated version was prepared as follows. The nonapeptide YAGAWNDL was iodinated with non-radioactive iodine by the method described by Hunter and Greenwood (1962) . Iodinated nonapeptide was purified by reverse-phase HPLC and 5 mg were then tritiated by catalytic halogen-tritium exchange with tritium gas (Amersham International pic, Amersham, Bucks, UK). Tritiated YAGAWNDL was purified by reverse-phase HPLC. Two milligrams were recovered, as determined by measurement of the optical density at 229 nm and comparison with that of unlabelled nonapeptide as standard. This 2 mg contained 18.4 mCi of radioactivity (specific activity of 8.4Ci mmol"). The tritium-labelled peptide was stored at -70°C either lyophilized, in water + 2% ethanol or in water + 50% ethanol. The latter condition afforded the greatest stability, yielding less than 5% decomposition over 1 year.
To study the nonapeptide stability 4!J..Ci rHjYAGAV-VNDL were diluted 1 part in 100 with either H 2 0 or HSV-1-infected cell extract which had been partially purified by ammonium sulphate precipitation (Dutia et al., 1986) . Twenty-five microlitres of each sample were analysed by reverse-phase HPLC and the eluant was monitored for radioactivity. Each sample was injected onto the column within 2 min after mixing. Figere 1a demonstrates that rHjYAGAWNDL diluted with H 2 0 was eluted from the column as a single peak at 7
Peak Amino acid composition" 1 Y 2 A(2), G(1), V(2), N(1), D(1), L(1) 3 Y(1), A(2), G(1), V(2), N(1), D(1), L(1) Fig. 2 . Purification of the products of YAGAWNDL by reverse-phase HPLC. The products formed upon incubation of YAGAWNDL with an extract of HSV-1-infected cells were separated by reverse-phase HPLC on a uBondapak C18 preparative column (19mm x 30cm) in a linear gradient changing from 100% H20 + 0.05% TFA to 100% acetonitrile + 0.05% TFA between 0 and 50 min using a flow rate of 10ml min-1 • The eluant was monitored at 229nm.
Confirmation that Peak 1 was tyrosine was obtained by . the observation that the retention times on analytical reverse-phase HPLC of Peak 1 and authentic tritiumlabelled tyrosine (Amersham International pic) were the same. Further, the retention times of Peak 2 and Peak 3 were identical with those of authentic AGAWNDL and YAGAWNDL, respectively, confirming the identities shown in Table 1 (data not shown).
The relative amounts of tyrosine and the octapeptide AGAWNDL were determined by quantification of the areas under Peaks 1 and 2 (Fig. 2; 195603 and 16605 arbitrary units, respectively) and measuring their relative molar absorbance at 229 nm. The latter was determined to be 4.36. From these values it can be calculated that the molar abundance of the octapeptide relative to that of tyrosine was 0.37. This suggests that octapeptide may be further modified. Alternatively the label may be lost as tritium gas' or to water in processes catalysed by the extract. We have not attempted to identify other putative modified products as our primary objective was to establish conditions to prevent degradation of the nonapeptide.
The data we have obtained show that in extracts of H8V-1-infected BHK cells the nonapeptide YAGAWNDL is modified to yield free tyrosine and the octapeptide AGAWNDL and that the extent of modification is reduced in the presence of certain protease inhibitors. The best protection was conferred by bacitracin, a cyclic polypeptide. The simplest interpretation of these data is that the Stability of the RR-inhibitory peptide 225 amino terminal tyrosine is cleaved from the nonapeptide.
The data obtained have direct relevance to the goal of developing an antiviral agent based on the strategy of inhibiting the herpesvirus-encoded ribonucleotide reductase using the peptide YAGAWNDL as a lead compound. studied the relationship between chemical structure and inhibitory potencies of a series of peptides including fragments and analogues of YAGAV-VNDL. Deletion of the amino terminal tyrosine generates an octapeptide with only one-eighth of the inhibitory potency of the nonapeptide. These results suggest that a means of protecting the peptide bond between the amino-terminal tyrosine and the neighbouring alanine of YAGAWNDL would be necessary to produce a stable antiviral drug based on the nonapeptide. This may be possible by producing non-peptide analogues of the inhibitory nonapeptide.
